We are live on ! Find out more
CATX icon

Perspective Therapeutics

30 hedge funds and large institutions have $6.01M invested in Perspective Therapeutics in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% more ownership

Funds ownership: 0.76%0.78% (+0.02%)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

3% less capital invested

Capital invested by funds: $6.18M → $6.01M (-$174K)

3% less funds holding

Funds holding: 3130 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.84%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
6
Reduced
6
Closed
4
Calls
Puts
Net Calls
Net Calls Change

CATX Hedge Fund Activity: Q3 2015 in Review

30 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2015, worth a combined $6.01M — down 2.8% from $6.18M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CATX and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 6 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $293K. The largest seller was AQR Capital Management, cutting an estimated $145K.

  • 30 institutional investors held Perspective Therapeutics (CATX) as of Q3 2015, down from 31 in Q2 2015.
  • Funds reported $6.01M of Perspective Therapeutics stock for Q3 2015, down 2.8% quarter-over-quarter.
  • 3 funds opened new Perspective Therapeutics positions in Q3 2015 and 4 closed out, a net change of -1 holder.
  • The largest Perspective Therapeutics buyer in Q3 2015 was BlackRock Institutional Trust, an estimated $293K added.
  • The largest Perspective Therapeutics seller in Q3 2015 was AQR Capital Management, an estimated $145K sold.

Based on aggregated 13F filings for Q3 2015.